Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case

United Therapeutics Corporation (NASDAQ:UTHR) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 2, Jefferies reiterated its “Buy” rating and a price target of $564 for United Therapeutics Corporation (NASDAQ:UTHR). This decision comes amid ongoing legal proceedings related to a patent dispute. The patent dispute involves interpretations of a recent Bayer case. Judge Andrews is currently reviewing letters from both parties about whether certain dependent claims (claims 5, 6, 9 & 17) have sufficient “patentable weight” for the case’s anticipation/obviousness analysis.

Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case

adriaticfoto/Shutterstock.com

If only these dependent claims are found valid and infringed, United Therapeutics could block competitor Yutrepia or seek damages, but only for products or uses that meet the narrower requirements of those claims. The next step is a court order on the “patentable weight” issue for dependent claims; both parties can appeal the decision.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company. It develops and commercializes therapies for pulmonary arterial hypertension (PAH) and other chronic and life-threatening conditions. Its key products include Remodulin, Tyvaso, Orenitram, and Unituxin.

While we acknowledge the potential of United Therapeutics Corporation (NASDAQ:UTHR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UTHR and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 13 Best Performing NASDAQ Stocks According to Hedge Funds and 10 High-Growth Semiconductor Stocks That Are Profitable in 2025.

Disclosure: None. This article is originally published at Insider Monkey.